Bumrungrad Hospital Public Company Limited
Bumrungrad Hospital Public Company Limited (BUHPF) Financial Performance & Income Statement Overview
Analyze Bumrungrad Hospital Public Company Limited (BUHPF) financial statements (income, balance sheet, and cash flow) across both yearly and quarterly periods.
Bumrungrad Hospital Public Company Limited (BUHPF) Income Statement & Financial Overview
Explore comprehensive income reports for Bumrungrad Hospital Public Company Limited BUHPF, broken down by year and quarter.
Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
---|---|---|---|---|
Revenue | $6.14B | $6.47B | $6.41B | $6.28B |
Cost of Revenue | $3.04B | $3.26B | $3.09B | $3.008B |
Gross Profit | $3.10B | $3.21B | $3.32B | $3.27B |
Gross Profit Ratio | $0.50 | $0.50 | $0.52 | $0.52 |
R&D Expenses | $0.00 | $0.00 | $0.00 | $0.00 |
SG&A Expenses | $1.08B | $1.14B | $1.003B | $1.007B |
Operating Expenses | $1.02B | $1.09B | $995.83M | $1.007B |
Total Costs & Expenses | $4.06B | $4.35B | $4.09B | $4.01B |
Interest Income | $63.39M | $65.61M | $73.56M | $78.82M |
Interest Expense | $2.03M | $2.05M | $2.12M | $2.06M |
Depreciation & Amortization | $255.71M | $274.84M | $268.95M | $266.53M |
EBITDA | $2.40B | $2.47B | $2.66B | $2.58B |
EBITDA Ratio | $0.39 | $0.38 | $0.42 | $0.41 |
Operating Income | $2.08B | $2.13B | $2.32B | $2.27B |
Operating Income Ratio | $0.34 | $0.33 | $0.36 | $0.36 |
Other Income/Expenses (Net) | $61.35M | $63.41M | $71.18M | $120.29M |
Income Before Tax | $2.14B | $2.19B | $2.39B | $2.39B |
Income Before Tax Ratio | $0.35 | $0.34 | $0.37 | $0.38 |
Income Tax Expense | $400.10M | $278.96M | $424.06M | $431.55M |
Net Income | $1.73B | $1.90B | $1.96B | $1.93B |
Net Income Ratio | $0.28 | $0.29 | $0.31 | $0.31 |
EPS | $2.18 | $2.39 | $2.46 | $2.43 |
Diluted EPS | $2.00 | $2.19 | $2.25 | $2.23 |
Weighted Avg Shares Outstanding | $794.93M | $794.91M | $794.91M | $794.91M |
Weighted Avg Shares Outstanding (Diluted) | $867.41M | $867.41M | $867.41M | $867.41M |
Over the past four quarters, Bumrungrad Hospital Public Company Limited demonstrated steady revenue growth, increasing from $6.28B in Q2 2024 to $6.14B in Q1 2025. Operating income reached $2.08B in Q1 2025, maintaining a consistent 34% margin over recent quarters. Despite fluctuations in R&D and SG&A expenses, EBITDA remained robust at $2.40B, reflecting operational efficiency. Net income dropped to $1.73B, with EPS at $2.18. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan